Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Ibsrela is a prescription medicine containing tenapanor. It is a sodium/hydrogen exchanger 3 inhibitor indicated for irritable bowel syndrome with constipation in adults. Each tablet contains 50 mg of tenapanor.
read more about ibsrela ...Tenapanor acts locally in the small intestine and colon by inhibiting sodium/hydrogen exchanger 3 on intestinal cells. This reduces sodium absorption, increases water secretion into the intestinal lumen, speeds intestinal transit, and softens stool.
Ibsrela is approved for adults with irritable bowel syndrome with constipation. Safety and efficacy are not established in patients younger than 18 years. It is contraindicated in children younger than 6 years and in patients with known or suspected mechanical gastrointestinal obstruction.
The recommended dose is 50 mg by mouth twice daily. One tablet is taken immediately before breakfast or the first meal of the day and another immediately before dinner. A missed dose is skipped rather than doubled.
Ibsrela carries a boxed warning for serious dehydration in pediatric patients. Severe diarrhea can also occur in adults. Treatment is suspended and the patient is rehydrated if severe diarrhea develops. Diarrhea, abdominal distension, flatulence, and dizziness are among the more common adverse reactions.
Ibsrela treats irritable bowel syndrome with constipation in adults.
The recommended dose is 50 mg twice daily immediately before the first meal of the day and before dinner.
Current labeling does not establish safety and efficacy below age 18 and contraindicates use in children younger than 6 years.
Current labeling directs suspension of Ibsrela and rehydration if severe diarrhea develops.
DailyMed - IBSRELA - tenapanor hydrochloride tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2102da5f-a1a0-4ac7-a1f6-38698cf7273a. Date Accessed October 2, 2026.
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation - A 12-Week, Placebo-Controlled Phase 3 Trial. https://pubmed.ncbi.nlm.nih.gov/31934897/. Date Accessed October 2, 2026.
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation - A 26-Week, Placebo-Controlled Phase 3 Trial. https://pubmed.ncbi.nlm.nih.gov/33337659/. Date Accessed October 2, 2026.
IBSRELA Prescribing Information. https://ardelyx.com/wp-content/uploads/2021/11/IBSRELA-Prescribing-Information-1.pdf. Date Accessed October 2, 2026.
Tenapanor (Ibsrela) - MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a622060.html. Date Accessed October 2, 2026.